Half the world’s adult population has metabolic syndrome or its downstream conditions
Quite likely either you or someone you know has metabolic syndrome or its downstream conditions...
Current treatments are imprecise "one-size-fits-all" medicines
A PILOT FOR PRECISION MEDICINE IN METABOLIC SYNDROME
Success of cancer precision medicines indicates what’s possible in metabolic syndrome-conditions
PRECISION THERAPEUTICS FOCUS THE RIGHT TREATMENT ON THE RIGHT PATIENT
The Market Potential
The oncology drugs market has grown from $10 billion in 2000 to over $140 billion in 2019
Estimated world metabolic syndrome drug market in 2040 after precision revolution is >$1.6 trillion
THE NEED FOR MULTIPLE OMICS
Metabolic syndrome-related conditions are multifactorial, requiring more complex data to unravel
METABOLIC SYNDROME DISEASE ORIGIN AND PROGRESSION ARE INFLUENCED BY MANY FACTORS BESIDES THE GENOME AND ALSO THEIR UNIQUE INTERACTIONS WITH ONE ANOTHER
WHAT WE ARE BUILDING
THE MOHSAIC® PLATFORM
MultiOmic’s process begins with the collection of biological samples along with clinical and outcome data
Multi-omics data is derived from these samples
Raw data from the vendors is pooled into a central data lake
The data lake is used to build artificial intelligence (AI)-enabled computational system biology models that are fine-tuned with wet lab experimentation
The model is utilized to identify endotypes, causal pathways and precision therapeutics
A PERFECT STORM—IN THE POSITIVE SENSE—IS FORMING FOR METABOLIC SYNDROME THERAPEUTICS
Data-DRIVEN THERAPEUTICS FOR WORLD'S #1 HEALTH PROBLEM
Want to be a part of our team?
Got a partnership in mind?
Get in touch with us and know more about how we are changing the face of healthcare.
Multiomic Health Limited is a registered UK company